Andrew Lucas, PharmD, MS, MS

Andrew Lucas has a diverse work experience in the field of pharmacology. Andrew is currently working as a Senior Scientist II at Pumas-AI, Inc. since February 2022. Prior to this, they served as the Associate Director of the Advanced Translational Pharmacology & Analytical Chemistry (ATPAC) Laboratory at the UNC Eshelman School of Pharmacy from November 2019 to February 2022.

Before joining UNC, Andrew worked as a Pharmacologist & Assistant Professor at the UNC Lineberger Comprehensive Cancer Center from February 2017 to February 2022. In this role, they led a research program focused on the application of clinical pharmacology in optimizing cancer treatment and developing new analytical platforms. Andrew contributed to various projects in basic drug discovery and translational pharmacology research.

From August 2016 to July 2019, Andrew worked as a Consultant Pharmacologist at MediGLO. In this role, they provided consulting services for preclinical and clinical drug development, with a specialization in PK/PD data analysis.

Andrew also has experience as a Post-Doctoral Fellow in Hematology/Oncology Drug Development at the UNC Eshelman School of Pharmacy from August 2014 to January 2017. During this time, they conducted research in genetic and physical screens for altered nanoparticle pharmacokinetics and developed methodologies in translational therapies. Andrew also served as a Teaching Assistant for Pharmacotherapy - Hematology/Oncology and supported course coordinators in various tasks.

In addition, Andrew has worked as a Pharmacy Clinical Clerkship at UNC Health Care from May 2013 to April 2014 and as a Research Associate at the UNC Eshelman School of Pharmacy from September 2010 to April 2014. Andrew has also worked as a Medical Chart Technology & Consolidation Consultant at Lucas Technologies from May 2003 to April 2014.

Andrew's early work experience includes working as a Research Assistant at Virginia Tech from October 2005 to May 2010. In this role, they conducted research on the connection between circadian proteins and cancer development, utilizing techniques of molecular biology and structural biology/biophysical characterization.

Overall, Andrew Lucas has a strong background in pharmacology, with expertise in clinical pharmacology, PK/PD principles, drug development, and translational research.

Andrew Lucas, PharmD, MS, MS has an extensive education history. Andrew obtained their Bachelor of Arts (BA) degree in Chemistry and Bachelor of Science (BS) degree in Biological Sciences from Virginia Tech in the years 2005 to 2009. In addition, they also completed a Master of Science (MS) degree in Biological Sciences with a focus on Cell and Molecular Biology from Virginia Tech between 2008 and 2010.

Moving forward, Andrew pursued their Doctor of Pharmacy (PharmD) degree from the UNC Eshelman School of Pharmacy from 2010 to 2014. Following this, they completed a Hematology/Oncology Drug Development Fellowship at the same institution between 2014 and 2017.

Further adding to their credentials, Andrew obtained a second Master of Science (MS) degree in Pharmacometrics from the University of Maryland, Baltimore Graduate School from 2019 to 2021.

Andrew also possesses various certifications. Andrew completed didactic training to fulfill the 10 US CFR 35.55 200-hour requirement for Authorized Nuclear Pharmacists in 2014. Additionally, they completed the CITI Biomedical Research Training, Good Clinical Practice Training, and GCP for Clinical Trials with Investigational Drugs, Biologics, and Devices Training in 2013. Andrew also holds certifications such as the American Society for Clinical Pathology Board of Certification Specialist in Cytometry [SCYM(ASCP)] obtained in 2017. Moreover, they are licensed by both the North Carolina Board of Pharmacy (2014) and the Virginia Board of Pharmacy (2015).